Document Detail

New Antiobesity Agents: Lorcaserin (Belviq) and Phentermine/Topiramate ER (Qsymia).
MedLine Citation:
PMID:  24304809     Owner:  NLM     Status:  In-Data-Review    
Obesity is a risk factor for a wide range of conditions, including cardiovascular disease. Although lifestyle modifications remain the cornerstone for the management of obesity, pharmacologic agents may be a helpful addition to patients who have comorbidities and do not respond adequately to diet and exercise. Lorcaserin and phentermine/topiramate ER are 2 long-awaited agents, approved in 2012 for obesity management, 13 years since orlistat received US Food and Drug Administration approval in 1999. Lorcaserin is a serotonin agonist, whereas phentermine/topiramate is a combination of a sympathomimetic agent and an antiepileptic drug; both these agents have been shown to reduce weight significantly and improve cardiovascular and metabolic parameters, such as blood pressure, lipids, and HbA1C. This article reviews the pharmacology and clinical efficacy and safety of each of these agents. The differences among the three available agents for long-term management of obesity will also be examined.
Grace Shyh; Angela Cheng-Lai
Related Documents :
12779279 - Design and evaluation of matrix diffusion controlled transdermal patches of verapamil h...
11741209 - Evaluation of polyoxyethylene homopolymers for buccal bioadhesive drug delivery device ...
18167219 - In vitro permeability of round window membrane to transforming dexamethasone with deliv...
15763629 - Influence of micro-environmental ph on the gel layer behavior and release of a basic dr...
19553179 - Effect of channeling agents on the release pattern of theophylline from kollidon sr bas...
14519679 - Continuous-release or burst-release of the antimicrobial peptide human lactoferrin 1-11...
23834829 - Pharmacoscintigraphy confirms consistent tamsulosin release from a novel triple-layered...
7338559 - Record-linked audit of drug utilization data in a hospital: antimicrobial use on a urol...
902689 - Antiarrhythmic and electrophysiological effects of ch-200.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Cardiology in review     Volume:  22     ISSN:  1538-4683     ISO Abbreviation:  Cardiol Rev     Publication Date:    2014 Jan-Feb
Date Detail:
Created Date:  2013-12-05     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9304686     Medline TA:  Cardiol Rev     Country:  United States    
Other Details:
Languages:  eng     Pagination:  43-50     Citation Subset:  IM    
From the *Department of Pharmacy, Kingsbrook Jewish Medical Center, Brooklyn, NY; and †Montefiore Medical Center, Bronx, NY.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Air pollution exposure as a risk factor for cardiovascular disease morbidity and mortality.
Next Document:  Erdheim-Chester disease and pituitary involvement: a unique case and the literature.